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Abstract
Introduction: Menopause is the termination of menstrua-
tion and fertility. Women commonly experience sleeping 
problems during the menopausal period. Aromatherapy is 
among the complementary therapies used to remedy sleep-
ing problems. Methods: This study aims to investigate the 
effects of lavender oil on sleep and quality of life of meno-
pausal women through steam inhalation. This study was 
quasi-experimental with pre-test/post-test placebo control 
groups. It was conducted with 57 women, 27 of whom were 
subject to aromatherapy and 30 to a placebo. Data were col-
lected using the Questionnaire Form, the Pittsburgh Sleep 
Quality Index (PSQI) and the Menopause-Specific Quality of 
Life Questionnaire (MENQOL). Results: For the intervention 
group, the PSQI median scores after the administration of 
aromatherapy were found to be significantly lower than 
those before the administration (p < 0.001) and those of the 
placebo group (p < 0.001). Similarly, for the intervention 
group, the total median MENQOL scores after the adminis-
tration of the aromatherapy were found to be significantly 
lower than the scores prior to the administration (p < 0.001) 
as well as the scores of the placebo group (p < 0.001). Con­
clusion: It was found that aromatherapy involving lavender-
scented steam inhalation increased sleep quality and quality 
of life in women with sleep deprivation problems during 
menopause. © 2020 S. Karger AG, Basel
Auswirkungen der Aromatherapie auf die Schlaf- 
und Lebensqualität menopausaler Frauen mit 
Schlafproblemen: Eine nicht randomisierte, 
placebokontrollierte Studie
Schlüsselwörter
Menopause · Schlafqualität · Lebensqualität · 
Aromatherapie · Lavandula angustifolia
Zusammenfassung
Einleitung: Die Menopause ist das Ausbleiben der Men-
struation und das Ende der Fruchtbarkeit. Viele Frauen ha-
ben in dieser Lebensphase Schlafprobleme. Aromathera-
pie ist einer der komplementären Behandlungsansätze, 
die zur Abhilfe bei Schlafproblemen verfolgt werden. 
Methoden: Das Ziel dieser Studie ist es, die Auswirkungen 
von Lavendelöl in Form von Dampfinhalationen auf die 
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Schlaf- und Lebensqualität menopausaler Frauen zu 
beurteilen. Die Studie war quasi-experimentell aufge-
baut, mit Prä-Test-/Post-Test-Untersuchungen und einer 
Placebo-Kontrollgruppe. Sie wurde mit 57 Frauen durch-
geführt, von denen 27 eine Aromatherapie erhielten und 
30 eine Placebobehandlung. Die Datenerhebung erfolgte 
mit dem Pittsburgh Sleep Quality Index (PSQI), dem 
Menopause-Specific Quality of Life Questionnaire (MEN-
QOL) und einem selbstentwickelten Patientenfragebo-
gen. Ergebnisse: In der Interventionsgruppe waren die 
medianen PSQI-Scores nach Anwendung der Aromathe-
rapie signifikant niedriger als vor der Anwendung (p < 
0,001) und als in der Placebogruppe (p < 0,001). Ebenso 
waren in der Interventionsgruppe die medianen MEN-
QOL-Gesamtscores nach Anwendung der Aromatherapie 
signifikant niedriger als vor der Anwendung (p < 0,001) 
und als in der Placebogruppe (p < 0,001). Schlussfolge­
rung: Die Autoren gelangten zu dem Schluss, dass die Aro-
matherapie mittels Dampfinhalation mit Lavendelduft die 
Schlafqualität und Lebensqualität von Frauen mit Schlaf-
mangel in der Menopause signifikant verbesserte.
© 2020 S. Karger AG, Basel
Introduction
According to the World Health Organization, meno-
pause is the permanent termination of menstruation as a 
result of the loss of ovarian activity. It is considered a very 
important period in women’s lives, especially due to its 
effects on quality of life [1, 2]. The age at which most 
women reach menopause varies between 43.8 and 53 
years in the world [3]. The most commonly observed 
symptoms of menopause that affect the quality of living 
are vasomotor changes, sleeplessness and fatigue [3, 4]. 
Hot flashes are experienced by more than 75% of women 
in the menopausal period [5]. Along with hot flashes, 
sleeplessness is reported as a major complaint during the 
menopausal period [5].
The prevalence of sleeping difficulties varies demo-
graphically, with an overall range between 12 and 79% of 
women in the world [6–11]. Night-time sleep disorders 
cause daytime somnolence or feelings of excessive day-
time sleepiness, reduced ability to concentrate and fluc-
tuations in mood, all of which combine to influence over-
all life quality. Additionally, sleep disorders increase the 
risk of coronary heart disease by affecting physiological 
functions, such as metabolic flexibility and insulin resis-
tance [12]. It has also been reported that the use of sleep-
ing pills increases from 5.8 to 11.2% among the popula-
tion during menopause [10].
In the past, women were encouraged to undergo hor-
mone replacement therapy (HRT) to reduce frequently ob-
served menopausal symptoms such as those resulting from 
vasomotor changes and sleep disorders [13, 14]. However, 
many concerns have been raised surrounding the use of 
HRT, including its correlation with breast cancer [15, 16]. 
In addition to the risk of turning benign breast diseases 
into breast cancer, HRT is also linked to endometrial can-
cer due to the single use of oestrogen, increased cardiovas-
cular and thromboembolism risk when HRT is initiated a 
long time after menopause, and an increase in gall bladder 
diseases causing pain and resulting in sleep disorders [17, 
18]. For these reasons, alternative methods are currently 
recommended to reduce menopausal symptoms. In recent 
years, complementary and alternative medicine (CAM) 
methods have become widely recommended [19, 20]. 
The prevalence of the use of CAM varies across coun-
tries, based on diverse cultural and social background fac-
tors [21]. A systematic review included 51 reports from 
49 studies in 15 countries, and the estimates of CAM use 
over 12 months ranged from 9.8 to 76% of the population 
in these studies [22]. CAM practices were reported as be-
ing used by 38% in the USA, 26% in the UK and 52% in 
Australia [22]. Among studies on national samples, the 3 
highest rates of CAM use were reported in East Asian 
countries: Japan with 76%, followed by South Korea with 
75% and Malaysia with 56% [22]. As for Turkey, reported 
CAM use ranges from 14.3 to 61% [23–27], especially in 
studies conducted on cancer patients. It is noteworthy 
that in Turkey, the development of complementary and 
traditional treatment methods has increasingly been re-
ceiving official support [28]. While aromatherapy is not 
a distinct discipline in the country, it is practiced as a sub-
field of phytotherapy [29].
Aromatherapy is one of the most widely used comple-
mentary therapies around the world [30]. In fact, a sys-
tematic review by Posadzki et al. [31] found that herbal 
medicine was the most popular type of CAM, followed by 
homeopathy, aromatherapy, reflexology and relaxation. 
Aromatherapy has been used by women for health rea-
sons for a long time [32]. During menopause, in particu-
lar, many types of essential oils, such as geranium, rose, 
clary sage, fennel, cypress, angelica and lavender oil, have 
been used for aromatherapy [33].
One type of essential oil used in aromatherapy is laven-
der oil [32, 34, 35]. Known in the scientific world as La-
vandula angustifolia, lavender is a member of the mint 
family. Its active ingredients are linalyl acetate and lin-
alool, which acts as a tranquilizer, affecting the aminobu-
tyric acid receptors in the central nervous system [36]. The 
resulting sedative effects of lavender oil help reduce stress-
related tension, irritability, insomnia and depression [32, 
34, 35]. Lemon oil (Citrus limon) also has many positive 
effects, such as providing mental refreshment and a sense 
of stability and comfort [32, 35]. Aromatherapy studies 
focusing on menopausal symptoms have shown that lav-
ender aromatherapy has an alleviating effect [34, 37]. On 
The Effect of Aromatherapy on Sleep and 
Quality of Life in Menopausal Women
423Complement Med Res 2020;27:421–430
DOI: 10.1159/000507751
the other hand, studies on aromatherapy’s effects on mid-
dle-aged women’s autonomic nervous system have found 
that it effectively accelerates the first phase of sleep, aids 
comfortable REM sleep and increases total sleep quality 
and duration [38]. Lavender aromatherapy has also been 
observed to help with the reduction of sleep disorders [39] 
and to increase the overall quality of sleep [40]. While 
there is a large number of studies published on the medi-
cal effects of lavender oil [37, 38, 40–42], despite all of our 
efforts, we have not found any studies on the effects of 
lavender aromatherapy via steam inhalation on women’s 
sleep and quality of life during the menopausal period. 
This study aims to remedy this shortcoming.
Study Hypotheses
Hypothesis 1. Aromatherapy applied to women with 
sleeping problems during menopause increases their 
sleep quality.
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Hypothesis 2. Aromatherapy applied to women with 
sleeping problems during menopause increases their 
quality of life.
Material and Methods 
Trial Design
This study was quasi-experimental with pre-test and post-test 
placebo control groups. 
Study Settings
The study was conducted in a province of the central Anatolian 
region of Turkey, between December 15, 2015, and December 23, 
2016.
Sample Size
The study population was made up of 1,471 women aged 45–59 
years, registered at a local Family Healthcare Centre. The number 
of individuals to be included in the sample groups was determined 
based on the sample sizes used in similar studies [34, 38, 43–47]. 
Therefore, the aim at the beginning of the study was to reach 60 
women, 30 for the intervention group and 30 for the placebo 
group. However, taking into account the possibility of losses, the 
intervention group was increased to 40 women and the placebo 
group to 36 women, all complying with the research criteria. The 
women to be included in the study from the Family Healthcare 
Centre were recruited using a snowball sampling method (Fig. 1). 
The 2 groups were not studied simultaneously to prevent them 
from influencing each other. Instead, the study with the interven-
tion group was conducted first, followed by that of the placebo 
group. The intervention group initially included 40 women. How-
ever, several of these women left the study later, citing headaches 
or claiming the research period was too long to complete. For these 
reasons, the intervention group was ultimately completed with a 
total of 27 women (Fig. 1). The placebo group (subject to plain 
steam inhalation) began with 36 women. However, 6 of the wom-
en later left, claiming the study duration was too long. In the end, 
the placebo group completed with a total of 30 women (Fig. 1).
At the end of the study, statistical power analysis was carried 
out based on the data collected from the sample groups during the 
study. Taking the Pittsburgh Sleep Quality Index (PSQI) and the 
Menopause-Specific Quality of Life Questionnaire (MENQOL) as 
our base reference points, the statistical power was estimated at 
99.9%, with α = 0.05 in the study. According to the result of the 
power analysis, we decided that the sample size was appropriate 
for our research.
Eligibility Criteria for Participants
To be eligible for inclusion in the study sample, women were 
required to have been in their menopausal period for 1–5 years, 
have a PSQI score of 5 or higher, not to have been undergoing 
HRT, have no allergies to aromatherapy products and be able to 
read and write. 
In addition, women were ineligible to participate in the re-
search if they had a known allergy to the essential oils to be applied 
in the study; had any sight-, hearing- and smelling-related or men-
tal disabilities; had low tolerance for the essential oil to be used or 
found its scent displeasing; were undergoing various complemen-
tary and supporting therapies or treatments, such as yoga, medita-
tion, and massage; were suffering from any type of respiratory dis-
orders, such as asthma or chronic obstructive lung disease, or any 
kind of heart disease, hypertension and/or diabetes; had been us-
ing sleeping pills; had a mental disorder or were suffering from 
serious psychological problems; were unable to perform inhalation 
as recommended or had been experiencing problems related to 




Lavender oil has a sedative effect that helps reduce the adverse 
effects of stress-induced tension, irritability, insomnia and depres-
sion [32, 34, 35]. On the other hand, lemon oil has refreshing ef-
fects that aid psychological relief and offer a sense of stability [32, 
35]. Due to these effects, these essential oils were recommended for 
the study by an aromatherapy expert, in line with the academic 
literature on the subject [35, 48].
Expert opinion was taken into consideration in terms of the 
method of administration for aromatherapy in this study [35]. 
Steam inhalation is deemed to be the fastest and easiest way to 
maximize the effects of essential oils [33] and is one of the most 
commonly used methods for aromatherapy. Not only does it not 
require specialized equipment, this method also increases the sol-
ubility of oil [30, 33, 41]. For these reasons, steam inhalation of oils 
was the technique opted for in our study.
Procedures Applied to the Intervention Group
During the first interview with each participant, the aim of the 
study was explained, and written and verbal consent were ob-
tained. The Questionnaire Form, PSQI and MENQOL were filled 
in by the researcher; pulse rate and blood pressure were taken; and 
the Inhalation Guide was explained followed by a demonstration 
of the aromatherapy administration method. No recommenda-
tions were made regarding the participant’s bedtime routines, but 
explicit instruction was given that inhalation should be performed 
just before going to bed. 
For the intervention group, the 2 oils (L. angustifolia and C. 
limon) were given to the participants in separate bottles without 
being mixed. The inhalation was carried out in line with the litera-
ture and the expert advice [35, 43–45]. Accordingly, 200 mL of 
boiling water was to be poured into a bowl (a non-plastic medium-
sized bowl, which could easily be found in any home in women’s 
homes). Two drops of lavender oil and 2 drops of lemon oil, kept 
in their own separate bottles, were to be added to boiling water to 
infuse the steam. The participants were asked to inhale the steam 
through the nose and exhale through the mouth for 5 min with 
their heads under a cover, 30 cm from the bowl. The inhalation 
procedure started on the first day after the initial interview and was 
carried out daily over 30 days. To ensure that the participants did 
not face any problems during the implementation and for the sake 
of the continuity of their participation, we had a motivational 
phone conversation with them every evening. 
Procedures Applied to the Placebo Group
Based on the advice of the aromatherapy expert, only plain, 
boiling water was administered to the placebo group, without any 
oils [35]. Therefore, the women were asked to inhale plain steam, 
prepared following the above-mentioned steps; i.e., excluding any 
essential oils, through the nose, and exhale from the mouth 30 cm 
from the bowl for 5 min, under a cover. The inhalation procedure 
started on the first day after the initial interview and was per-
formed daily over 30 days. The daily phone calls intended to sus-
tain participant motivation throughout the duration were simi-
larly made to the members of the placebo group by a researcher. 
Participants from both groups were told to close their eyes dur-
ing inhalation and to perform the administration in the same way 
throughout the duration of the study. The women’s vital signs were 
checked during the initial and final interviews. 
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Data Collection
In this study, the data were recorded by the researcher during 
face-to-face interviews with the participants in the participants’ 
own homes, each lasting 10–15 min. The daily routines of the 
women were not interfered with at any point in the study. The 
Questionnaire Form, the PSQI and the MENQOL scales were filled 
in for the members of both the intervention and the placebo groups 
as pre-test, and their pulse rate and blood pressure were taken and 
noted down. One month after the beginning of the study, the wom-
en were asked to respond to the PSQI and MENQOL scales once 
again, and their pulse rate and blood pressure were taken by the 
researcher. Moreover, to ensure consistency in the implementa-
tion, the participants were called daily on their personal phones. 
Outcome Measures
The data for this study were collected through face-to-face in-
terviews using the Questionnaire Form, the PSQI and the MEN-
QOL.
Questionnaire Form. This form was developed by the research-
ers in accordance with the existing literature on the topic [7, 8, 49] 
and consisted of 14 questions related to sociodemographic and 
obstetric features as well as the age and height of the participants. 
The participants’ blood pressure and pulse rate, which were taken 
by the researcher, were also recorded in this form. The form was 
completed by means of face-to-face interviews.
Pittsburgh Sleep Quality Index. The PSQI was developed in 
1989 by Buysse et al. [50]. The reliability and validity studies were 
conducted by Ağargün et al. [51] (1996) in Turkey, and Cronbach’s 
α was found to be 0.80. The scale consisted of 18 items and 7 com-
ponent scores. Each component was assigned a value between 0 
and 3 for evaluation. The total of these points yielded the total 
score of the scale, which ranged from 0 to 21. A high score (5 or 
above) indicated poor sleep quality. Sleep quality was classified as 
good (0–4) and poor (5–21). Given that one of the study criteria 
was the use of sleeping pills before and during the study, the sub-
dimension of the use of a sleeping pill (component 6) was not used 
for calculation [51].
Menopause-Specific Quality of Life Questionnaire. This ques-
tionnaire was developed by Hilditch et al. [52] in 1996 to gather 
information about menopause-specific quality of life with psycho-
metric features based on women’s experiences and was adapted to 
Turkish society by Kharbouch and Sahin [53] in 2005, ensuring its 
reliability and validity. The scores for each sub-section of MEN-
QOL range from 1 to 8. In the questionnaire, 1 point indicates that 
no problems related to menopause are experienced, 2 points indi-
cate the existence of mild problems but not enough to cause dis-
tress, and 3–8 points denote increasing severity in the associated 
problems. The questionnaire consists of 4 parts corresponding to 
different aspects of the problem: vasomotor, psycho-social, physi-
cal and sexual. The vasomotor section (Questions 1–3) evaluates 
whether and to what degree a participant suffers from feelings of 
intense or uncomfortable body heat and night sweats during 
menopause. The psycho-social section (Questions 4–10) includes 
questions regarding the participants’ sense of well-being by assess-
ing feelings of lack of contentedness with one’s own life, stress-
related tension, dysmnesia, depression, grief, exhaustion, intoler-
ance towards others, feelings of insufficiency and a desire for soli-
tude. The physical features section of the Questionnaire Form 
Table 1. Descriptive characteristics of the participants
Characteristics Intervention group (n = 27) Placebo group (n = 30) pa
M (Q1–Q3) mean rank M (Q1–Q3) mean rank
Age, years 53.00 (51.00–55.00 29.07 53.00 (50.00–55.00 48.93 0.974
Age at of menopause onset, years 51.00 (46.00–52.00) 28.24 50.00 (48.00–52.00) 29.68 0.739
Duration of menopause, years 3.00 (1.00–4.00) 30.35 3.00 (2.00–3.00) 27.78 0.552
n % n % pb
Marital status
Married 24 88.9 20 66.7 0.061Single 3 11.1 10 33.3
Educational status
Literate/primary school graduate 13 48.1 11 36.7
0.547Secondary school graduate 5 18.5 9 30.0
High school graduate and above 9 33.3 10 33.3
Occupational status
Employed 5 18.5 5 16.7 0.854Unemployed 22 81.5 25 83.3
Income level
Low 4 14.8 3 10.0
0.707Moderate 20 74.1 25 83.3
High 3 11.1 2 6.7
Body mass index
<25 (normal) 3 11.1 8 26.7
0.10925–30 (overweight) 10 37.0 14 46.7
≥30 (obese) 14 51.9 8 26.6
M, median; Q1, 25th percentile; Q3, 75th percentile. a Mann-Whitney U test. b χ2 test. 
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(Questions 11–26) evaluates general symptoms, such as flatulence 
and pain, pain in the muscles and joints, fatigue, sleeping difficul-
ties, head and neck pain, reduced physical power, energy and en-
durance, dry skin, weight gain, increase in facial hair, changes in 
appearance, flexibility and/or skin colour, distension, backaches, 
polyuria and urinary incontinence while coughing or laughing. 
The sex-related section of the Questionnaire Form (Questions 27–
29) involves questions about symptoms such as changes in sexual 
desire, vaginal dryness during intercourse and sexual abstinence. 
Cronbach’s α values for the assessment were α = 0.73 for the vaso-
motor section, α = 0.84 for the psychomotor section, α = 0.88 for 
the physical section and α = 0.84 for the sexual section [53].
Inhalation Guide for the Intervention Group. This guide was 
prepared by the researchers in line with the existing academic lit-
erature [33, 43] and the aromatherapy expert’s opinion [35], in 
order to explain the steps related to the inhalation and other points 
to be considered. The guide included instructions for preparing 
the hot water mixture containing the essential oils (L. angustifolia 
and C. limon), the method and duration of application, and what 
to do after the administration. This guide was given to the women 
in the intervention group after the steps were demonstrated (sec-
tion Procedures Applied to the Intervention Group).
Inhalation Guide for the Placebo Group. The inhalation guide 
for the placebo group was prepared by the researchers, similarly 
drawing on the existing literature [33, 43] and the expert’s opinion 
[35]. As with the intervention group, the guide was given to the 
participants in the placebo group once the inhalation steps had 
been clearly explained and demonstrated.
The Instrument for the Blood Pressure Measurement. A cali-
brated, semi-automatic blood pressure monitor (Microlife BP-
3BTO-H), which measures from the upper arm, was used to take 
blood pressure.
Table 2. PSQI sub-dimension medians and differences in the intervention and placebo groups before and after aromatherapy applica-
tion
PSQI sub-dimensions Intervention group (n = 27) Placebo group (n = 30) pb
M (Q1–Q3) mean rank M (Q1–Q3) mean rank
Subjective sleep quality
Before 2.00 (2.00–2.00) 24.78 2.00 (2.00–3.00) 32.80 0.029
After 1.00 (1.00–1.00) 14.00 2.00 (2.00–2.00) 42.50 <0.001
Difference 1.00 (1.00–1.00) 39.48 0.00 (0.00–0.25) 19.57 <0.001
pa <0.001 0.008
Sleep latency
Before 3.00 (3.00–3.00) 30.44 3.00 (3.00–3.00) 27.70 0.203
After 2.00 (1.00–2.00) 17.33 3.00 (3.00–3.00) 39.40 <0.001
Difference 1.00 (1.00–2.00) 40.65 0.00 (0.00–0.00) 18.52 <0.001
pa <0.001 0.480
Sleep duration
Before 3.00 (3.00–3.00) 26.72 3.00 (3.00–3.00) 31.05 0.064
After 2.00 (1.00–2.00) 16.78 3.00 (3.00–3.00) 40.00 <0.001
Difference 1.00 (0.00–1.00) 40.24 0.00 (0.00–0.00) 18.88 <0.001
pa <0.001 0.317
Habitual sleep efficiency
Before 3.00 (3.00–3.00) 27.26 3.00 (3.00–3.00) 30.57 0.126
After 3.00 (2.00–3.00) 23.13 3.00 (3.00–3.00) 34.28 <0.001
Difference 0.00 (0.00–1.00) 33.94 0.00 (0.00–0.00) 24.55 0.006
pa 0.002 0.257
Sleep disturbances
Before 2.00 (2.00–2.00) 30.67 2.00 (2.00–2.00) 27.50 0.311
After 2.00 (1.00–2.00) 25.28 2.00 (1.75–2.00) 32.35 0.052
Difference 0.00 (0.00–1.00) 34.22 0.00 (0.00–0.00) 24.30 0.005
pa 0.001 0.414
Daytime dysfunction
Before 2.00 (2.00–3.00) 29.87 2.00 (2.00–2.25) 28.22 0.638
After 1.00 (1.00–2.00) 19.85 2.00 (2.00–2.00) 37.23 <0.001
Difference 1.00 (1.00–1.00) 39.11 0.00 (0.00–0.00) 19.90 <0.001
pa <0.001 0.014
PSQI total
Before 15.00 (14.00–15.00) 26.04 15.00 (15.00–16.00) 31.67 0.177
After 10.00 (8.00–11.00) 14.22 15.00 (14.00–1500) 42.30 <0.001
Difference 5.00 (4.00–600) 43.69 0.50 (0.00–100) 15.78 <0.001
pa <0.001 0.014
PSQI score differences were calculated by subtracting the last follow-up score from the beginning score. Bold p values are statistically 
significant (p < 0.05). PSQI, Pittsburgh Sleep Quality Index; M, median; Q1, 25th percentile; Q3, 75th percentile. a Wilcoxon t test. 
b Mann-Whitney U test. 
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Statistical Analysis
The data were assessed using IBM SPSS 20.0 (Statistical Pro-
gram for the Social Sciences). The descriptive statistics were given 
as number of units (n), percentage (%) and median (Q1–Q3). The 
concordance of the numerical data to the normal distribution was 
evaluated by means of the Shapiro-Wilk test. The homogeneity of 
the variances was checked using the Levene test. The comparison 
of categorical variables was made using χ2 analysis. The compari-
son of the 2 independent groups was made using the Mann-Whit-
ney U test, and the evaluation of 2 consecutive measurements was 
done using the Wilcoxon test. In these comparisons, a value of p < 
0.05 was taken as statistically significant. 
Results
In the intervention group, the median age of the wom-
en was 53.00 (51.00–55.00) years, the median age at the 
onset of menopause was 51.00 (46.00–52.00) years, and 
the median menopause duration was 3.00 (1.00–4.00) 
years, while in the placebo group, the median age of the 
women was 53.00 (50.00–55.00) years, the median age at 
the onset of menopause was 50.00 (48.00–52.00) years, 
and the median menopause duration was 3.00 (2.00–
3.00) years. Age, marital status, educational level, occupa-
tional status and income level, as well as age at the onset 
of menopause and menopause duration, were found to be 
similar in both groups (Table 1; p > 0.05). The vital signs 
of the women were found to be within normal values be-
fore and after the administration of aromatherapy. 
Before the administration, the median PSQI score was 
determined to be 15.00 (14.00–15.00) in the intervention 
group and 15.00 (14.00–16.00) in the placebo group. Be-
fore the administration, median scores were received for 
all sub-dimensions of the PSQI scale except for the sub-
jective sleep quality sub-dimension, and total median 
scores were found to be similar for both groups (Table 2; 
p > 0.05). After the administration, the PSQI median 
score was determined to be 10.00 (8.00–11.00) in the in-
tervention group and 15.00 (14.00–15.00) in the placebo 
group (Table 2; p < 0.001). The total PSQI score decreased 
by 4 points for the intervention group and 1 point for the 
placebo group following 30 days of the administration of 
aromatherapy (p < 0.001). After the administration, a sig-
Table 3. MENQOL sub-dimension medians and differences in the intervention and placebo groups before and after the application of 
aromatherapy
MENQOL sub-dimensions Intervention group (n = 27) Placebo group (n = 30) pb
M (Q1–Q3) mean rank M (Q1–Q3) mean rank
Vasomotor symptoms
Before 14.00 (13.00 to 16.00) 22.83 19.00 (14.00 to 22.00) 34.55 0.007
After 12.00 (11.00 to 13.00) 17.65 18.00 (14.75 to 21.00) 39.22 <0.001
Difference 2.00 (1.00 to 3.00) 39.48 0.00 (–1.00 to 1.00) 19.57 <0.001
pa <0.001 0.407
Psychosocial symptoms
Before 39.00 (31.00 to 41.00) 25.89 39.50 (35.75 to 43.00) 31.80 0.179
After 38.00 (31.00 to 41.00) 25.50 40.00 (34.75 to 43.00) 32.15 0.130
Difference 0.00 (0.00 to 1.00) 30.37 0.00 (–0.25 to 1.00) 27.27 0.517
pa 0.368 0.662
Physical symptoms
Before 84.00 (77.00 to 90.00) 33.17 78.00 (69.75 to 85.50) 25.25 0.072
After 77.00 (70.00 to 80.00) 26.09 79.00 (72.50 to 85.00) 31.62 0.209
Difference 6.00 (5.00 to 10.00) 41.74 0.00 (–1.00 to 0.25) 17.53 <0.001
pa <0.001 0.488
Sexual symptoms
Before 19.00 (15.00 to 21.00) 32.11 16.00 (3.00 to 21.00) 26.20 0.176
After 19.00 (15.00 to 21.00) 32.11 16.00 (3.00 to 21.00) 26.20 0.176
Difference 0.00 (0.00 to 0.00) 29.00 0.00 (0.00 to 0.00) 29.00 1.000
pa 1.000 1.000
Total
Before 152.00 (144.00 to 161.00) 29.96 149.50 (137.50 to 164.00) 28.13 0.678
After 142.00 (131.00 to 155.00) 24.63 151.00 (137.50 to 161.25) 32.93 0.059
Difference 8.00 (7.00 to 13.00) 41.91 0.00 (–2.00 to 1.00) 17.38 <0.001
pa <0.001 0.887
Questions related to sexual symptoms were not answered by women who did not have a partner. MENQOL score differences were 
calculated by subtracting the last follow-up score from the beginning score. p values in bold are statistically significant (p < 0.05). 
MENQOL, Menopause-Specific Quality of Life Questionnaire; M, median; Q1, 25th percentile; Q3, 75th percentile. a Wilcoxon t test. 
b Mann-Whitney U test. 
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nificant difference was found between the intervention 
and placebo groups in terms of the median scores of all 
sub-dimensions and the total PSQI median scores (Table 
2; p < 0.05).
Before the administration, the MENQOL total median 
score was found to be 152.00 (144.00–161.00) in the in-
tervention group and 149.50 (137.50–164.00) in the pla-
cebo group (Table 3; p > 0.05). Before the administration, 
the median scores for all sub-dimensions of the MEN-
QOL scale, except for the vasomotor symptoms sub-di-
mension, and the total mean scores were measured to be 
similar for both groups (Table 3; p > 0.05). After the ad-
ministration, the total MENQOL median score was found 
to be 142.00 (131.00–155.00) in the intervention group 
and 151.00 (137.50–161.25) in the placebo group (Table 
3; p < 0.001).
After the administration, no significant differences 
were found between the 2 groups in the total median 
score of the MENQOL and in the median scores of all its 
sub-dimensions, except for vasomotor symptoms (Table 
3; p > 0.05). However, a statistically significant difference 
between before the administration and after the adminis-
tration was found between the 2 groups in the total me-
dian score of the MENQOL and in the median scores of 
all its sub-dimensions, except for psychosocial and sexual 
symptoms (Table 3; p < 0.001). 
Discussion
This study aimed to determine the effects of aroma-
therapy on the sleep quality and the overall quality of life 
of women who suffer from poor sleep quality during the 
menopausal period. At the end of our study, we saw that 
the PSQI scores of the intervention and placebo groups 
were similar before the administration of the aromather-
apy, indicating poor sleeping quality in both groups (Ta-
ble 2; p > 0.05). With the exception of sleep disturbances, 
all other sub-dimensions of the PSQI and the total scores 
increased after the administration in both the intervention 
and the placebo group; however, the sleep quality of the 
women in the intervention group improved more than 
that of the placebo group and at a significant level (Table 
2; p < 0.001). The total median PSQI score of the interven-
tion group was found to have decreased by 4 points after 
the administration of aromatherapy. This decrease in the 
PSQI score of the women in the intervention group sup-
ports the hypothesis that “aromatherapy applied to wom-
en with sleeping problems during menopause increases 
their sleep quality.” It was also found that steam inhalation 
without essential oils also increased sleep quality via the 
placebo effect, though the increase was not as significant 
as that in the intervention group. The total median PSQI 
score of the placebo group decreased by 1 point.
In recent years, aromatherapy has become a preferred 
method for eliminating the unfavourable symptoms that 
accompany menopause. In the existing academic litera-
ture, there are studies demonstrating the positive effects 
of aromatherapy on vasomotor symptoms [33, 37], psy-
chological symptoms [46] and abdominal fat and waist 
circumference reduction [42]. However, studies on the 
use of aromatherapy to alleviate sleeping problems dur-
ing the menopausal period are not as widely available in 
the literature. There are some studies that show an in-
crease in sleep quality when aromatherapy is used in gen-
eral. In this limited number of studies, sleep quality is 
shown to be better in aromatherapy intervention groups 
than in placebo groups [11, 38, 40, 44, 45]. But there may 
be differences in terms of the level of effect on sleep qual-
ity between the studies [38, 44, 54] conducted using only 
lavender oil and the current study, which was conducted 
using a combination of lavender and lemon oil.
In this study, inhalation aromatherapy administered 
to the intervention group was found to significantly de-
crease vasomotor and physical symptoms along with the 
total MENQOL score (Table 3). In a study by Hur et al. 
[34], it was found that aromatherapy through massage 
significantly reduced hot flashes, which are considered to 
be a major menopausal symptom. In a study conducted 
by Darsareh et al. [37] which compared the impacts of 
aromatic oil and regular oil massage, it was found that the 
menopausal symptom scores of the group to which aro-
matic oil was administered were significantly lower than 
those of the placebo group. Finally, in a study conducted 
by Taavoni et al. [47], it was observed that a massage with 
aromatherapy decreased the psychosocial sub-dimension 
score during the menopausal period more than a massage 
without aromatherapy. Our study findings are similar to 
those in the literature. 
A study by Kazemzadeh et al. [55] also found that in-
haling steam with lavender oil significantly decreased 
menopausal hot flashes in the intervention group com-
pared to the placebo group, while Choi et al. [56] found 
that aromatherapy using orange blossom oil alleviated 
menopausal symptoms and increased quality of life [56]. 
Our findings seem to be in line with these findings in the 
existing literature. The decrease in the total MENQOL 
scores of our participants in the intervention group sup-
ports our hypothesis that “aromatherapy applied to wom-
en with sleep problems during menopause increases their 
quality of life.” 
Eight women in the intervention group and 6 women 
in the control group (together making up 32% of the ini-
tial sample) left the study because they found the required 
duration of the administration of aromatherapy too long. 
We thought that the participants found the study espe-
cially challenging because aromatherapy was performed 
through the steam-inhalation method. Thus, we suggest 
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that similar studies should be done with more practical 
methods in the future (e.g., putting drops of oil on a cloth 
to smell).
Limitations 
Randomization was not implemented in this study. 
Therefore, there is the potential of observer bias.
Conclusion
Lavender inhalation aromatherapy improves sleep 
quality and quality of life in women with sleeping prob-
lems during menopause.
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